3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Spinal Cord Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Nervous System Diseases
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Epilepsy
1
Brain Neoplasms
1
Bone Marrow Diseases
1
Interventions
fludarabine
27
Azacitidine
26
venetoclax
23
Cyclophosphamide
22
Specimen Handling
21
fludarabine phosphate
17
Biopsy
16
Whole-Body Irradiation
15
Mycophenolic Acid
15
Busulfan
15
Melphalan
14
Cytarabine
14
Tacrolimus
13
Granulocyte Colony-Stimulating Factor
12
Decitabine
11
Stem Cell Transplantation
10
Injections
10
Cyclosporine
10
decitabine and cedazuridine drug combination
9
Sirolimus
9
Filgrastim
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
X-Rays
6
Idarubicin
6
ruxolitinib
5
Cyclosporins
5
Cladribine
5
Methotrexate
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Clinical Laboratory Techniques
×
90 days
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled